Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 19, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup...
-
Jun 9, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS® Cream 0.1%. The...
-
May 21, 2008Company to Acquire Minority Interest in New Entity
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has entered into a collaborative agreement with Cobrek Pharmaceuticals, a newly formed entity of Pentech Pharmaceuticals Inc., a...
-
May 20, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Citi Investment Research Global Health Care Conference on Wednesday,...
-
May 6, 2008- Third quarter revenue increased $141 million, or 39 percent, to $504 million on important new product launches
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its third quarter fiscal year 2008 and nine months ended March 29, 2008. Perrigo Company (in thousands, except per share...
-
May 1, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on June 20, 2008 to shareholders of record on May...
-
Apr 24, 2008
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) Nicotine Polacrilex...
-
Apr 23, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2008 on Tuesday, May 6, 2008 at approximately 8:00 a.m. (ET). The...
-
Apr 21, 2008
ALLEGAN, Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for over-the-counter...
-
Apr 14, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...
-
Mar 24, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum on...
-
Mar 20, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the United States District Court for the District of New Jersey has denied Connetics Corporation's motion for a preliminary...
-
Mar 11, 2008Court Issues Temporary Restraining Order
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...
-
Mar 6, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), has received final approval from the U.S. Food and Drug...
-
Mar 4, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at...
-
Feb 12, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...
-
Feb 5, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's Chairman and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device...
-
Feb 5, 2008Increases Full Year Guidance
-- Second quarter revenue increased $65 million, or 17 percent, to $435 million -- GAAP net income increased 63 percent to $34 million, or $0.36 per share -- Second quarter cash provided by...
-
Feb 1, 2008
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $150 million of the Company's common stock through February 1, 2010...
-
Jan 22, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2008 on Tuesday, February 5, 2008 at approximately 8:00 a.m. (ET)....
-
Jan 9, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired Galpharm Healthcare, Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom, privately-held...
-
Jan 4, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, January 9, at...
-
Dec 28, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...
-
Dec 10, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...
-
Nov 1, 2007-- First quarter revenue increased $43 million, or 12 percent, to $383 million
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2008 first quarter that ended September 29, 2007. Perrigo Company (in thousands, except per share...